Published on 4/24/2007 in the Prospect News PIPE Daily.
New Issue: Halozyme secures $32.1 million from private placement of stock
By Sheri Kasprzak
New York, April 24 - Halozyme Therapeutics, Inc. is gearing up to close a $32.095 million private placement.
The company received definitive agreements from New River Management V, LP to buy 3.5 million shares at $9.17 each.
San Diego-based Halozyme is a biopharmaceutical company focused on developing recombinant human enzymes for drug delivery, palliative care, oncology and infertility markets.
| Issuer: | Halozyme Therapeutics, Inc.
|
| Issue: | Stock
|
| Amount: | $32.095 million
|
| Shares: | 3.5 million
|
| Price: | $9.17
|
| Warrants: | No
|
| Investor: | New River Management V, LP
|
| Announcement date: | April 24
|
| Stock symbol: | Amex: HTI
|
| Stock price: | $8.95 at close April 23
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
